A Multicenter, Open Label, Phase 1 Dose Escalation Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of INC280 Tablet Formulation With Food in Patients With cMET Dysregulated Advanced Solid Tumors

Cancer type: Multiple diagnosis, Solide tumores

Phase: I

Principal Investigator: Yachnin Jeffrey

Country: SE

Keywords: Sweden, Stockholm, cMET

Status: Inclusion completed

Link to